Evidence map›Paper›PMID 42179746›Full record

ArticleAmerican journal of clinical and experimental immunology2026

Immune-metabolic crosstalk in rheumatoid arthritis: mediation effects of plasma metabolites on inflammatory cytokines.

Yuting Liang, Yanqiu Zhang, Jieyu Jin, Bin Feng, Jun Qiu, Jun Cao

Abstract read
In one paragraph

Article in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuting LiangCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu, China.
Yanqiu ZhangInstitute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anti-inflammatory Immune Drugs Collaborative Innovation Center Hefei 230032, Anhui, China.
Jieyu JinCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu, China.
Bin FengCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu, China.
Jun QiuCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu, China.
Jun CaoCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215000, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a chronic inflammatory condition defined by synovitis and progressive joint damage. The connection between inflammatory cytokines, molecules, and RA is still poorly understood despite the information combining both immune dysregulation and metabolic reprogramming to its pathophysiology.

methodsA two-sample Mendelian randomization (MR) analysis was carried out using summary statistics from the largest-scale genome-wide association study (GWAS) to examine the link between 91 inflammatory cytokines and RA risk. Metabolite pathways were identified through mediation analysis. Multiple MR Methods including inverse variance weighting (IVW) were used for causal estimation and the hypothesis was verified by sensitivity analysis.

resultsThe analysis results showed that there was a causal association between six inflammatory cytokines and RA. Among them, HGF and IL-10RA increased the risk of RA, while CXCL9, EN-RAGE, IFN-γ and CCL8 showed protective effects. These associations were validated using multiple MR methodologies, including inverse-variance weighting, MR-Egger regression, and leave-one-out sensitivity analyses. Further mediation MR analysis revealed seven metabolite-mediated pathways of inflammatory cytokines and RA. Specifically, the protective effect of CXCL9 was achieved in part by reducing plasma eicosapentaenoic acid (EPA; 20:5n3) levels (mediating effect = -0.007; proportion mediated = 8.10%). The protective effect of EN-RAGE was mediated by a decrease in the level of salicyluric glucuronide (mediating effect = -0.015; 12.70%). IFN-γ reduced the risk of RA through two independent metabolic pathways: reducing the level of 1-arachidonoyl-glycerol-3-phosphocholine (20:4n6) levels (mediating effect = -0.005; 4.67%), and increasing the ratio of glycine-to-pyridoxal (mediating effect = -0.020; 19.60%). In contrast, IL-10RA increases the risk of RA by increasing 3,7-dimethylurate (mediating effect = 0.011; 12.50%) and decreasing N, N-dimethylalanine levels (mediating effect = 0.010; 11.70%). The protective effect of CCL8 was mediated by the reduction of specific sphingomyelin species (d17:2/16:0, d18:2/15:0) (mediating effect = -0.012; 12.30%).

conclusionsThe results of this study not only confirmed the causal role of specific inflammatory cytokines in the pathogenesis of RA from a genetic perspective, but more importantly, for the first time, systematically revealed the specific plasma metabolite mediating pathways that connect these inflammatory cytokines to RA. These findings more specifically link the immune dysregulation of RA to metabolic remodeling, especially the protective role of IFN-γ through glycine/pyridoxal balance, and the pathway of IL-10RA through purine metabolites to affect risk, providing novel and mechanistic insights into the immunometabolic network of RA. We believe that these specific intermediate metabolites are expected to be potential candidate targets for future targeted therapies or intervention strategies, aiming to precisely regulate the interaction between inflammation and metabolism.

Indexed as

inflammationinflammatory cytokinesMendelian randomizationmetabolitesRheumatoid arthritis

Identifiers

PMID42179746
PMCPMC13194090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.